Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:171-178

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kusunoki, J.
Right arrow Articles by Sekine, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kusunoki, J.
Right arrow Articles by Sekine, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
*CYCLOHEXANE
Related Collections
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:171.)
© 2000 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Postprandial Hyperlipidemia in Streptozotocin-Induced Diabetic Rats Is Due to Abnormal Increase in Intestinal Acyl Coenzyme A:Cholesterol Acyltransferase Activity

Jun Kusunoki; Katsumi Aragane; Tetsuya Kitamine; Hideki Kozono; Kyoko Kano; Kouji Fujinami; Kazuhiro Kojima; Tsuyoshi Chiwata; Yasuo Sekine

From Pharmaceuticals Research Laboratories, Fujirebio Inc, Hachioji, Tokyo, Japan.

Correspondence to Jun Kusunoki, Pharmaceuticals Research Laboratories, Fujirebio Inc, 51 Komiya-cho, Hachioji, Tokyo 192-0031, Japan.

Abstract—Postprandial hyperlipidemia (PH) is recognized as a significant risk factor for cardiovascular disease. The present study, involving rats with streptozotocin (STZ)-induced diabetes, was performed to establish a PH model and to examine the relation between small intestinal acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity and serum lipid levels in the postprandial state. The small intestinal ACAT activities in normal rats during the experimental period were 4 to 5 pmol/mg protein per minute. In contrast, in the diabetic rats, the ACAT activities were 2 to 3 times higher than activities seen in normal rats from 7 to 21 days after the STZ injection in the absence of a high fat diet and hyperplasia in the gut. In an oral fat-loading test that used diabetic rats that had been injected with STZ (60 mg/kg) intravenously 14 days previously, the postloading changes in the serum concentrations of total cholesterol (TC) and triglyceride (TG) were significantly greater in the diabetic rats than in normal rats. Single oral administration of (1s,2s)-2-[3-(2,2-dimethylpropyl)-3-nonylureido]cyclohexane-1-yl 3-[(4R)-N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate (F-1394, 3 to 30 mg/kg), a potent ACAT inhibitor, suppressed the post–fat-loading elevation of serum TC levels in the diabetic rats in a dose-dependent manner without affecting serum glucose levels. Furthermore, the small intestinal ACAT activity, serum TG levels, and lymphatic absorption of TC and TG in the rats that were administered F-1394 (30 mg/kg) were reduced by {approx}90%, 70%, 30%, and 15%, respectively. This is the first evidence that elevated ACAT activity in the gut, unlike hyperplasia and hyperphagia, induces PH in rats. Our results strongly suggest that F-1394 may be a potential treatment for PH in humans.


Key Words: acyl coenzyme A:cholesterol acyltransferase • streptozotocin-induced diabetic rats • postprandial hyperlipidemia • F-1394 • fat-loading test




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Hori, M. Satoh, K. Furukawa, Y.-i. Sakamoto, H. Hakamata, Y. Komohara, M. Takeya, Y. Sasaki, A. Miyazaki, and S. Horiuchi
Acyl-Coenzyme A:Cholesterol Acyltransferase-2 (ACAT-2) Is Responsible for Elevated Intestinal ACAT Activity in Diabetic Rats
Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1689 - 1695.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Kusunoki, D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher
Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice
Circulation, May 29, 2001; 103(21): 2604 - 2609.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
K. Aragane, K. Fujinami, K. Kojima, and J. Kusunoki
ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits
J. Lipid Res., April 1, 2001; 42(4): 480 - 488.
[Abstract] [Full Text]